Leveraging AI-led Insights for Strategic Biosimilar Licensing Negotiations

Both companies had developed various models to understand biosimilar price erosion but faced significant barriers.

They relied on list price data from market vendors, which offered unreliable assumptions, and consulting firm interviews that provided insufficient clarity into the evolving dynamics.

Additionally, they couldn’t grasp the role of non-price factors affecting tender wins and originator defence, leading to uncertain strategic planning.

Recognising these challenges, a C-level executive approached Vamstar for deeper insights into the biosimilars market.

Vamstar leveraged its Global Tendering Datasets to identify, capture, and normalise relevant data from tender contracts and documents spanning five years from 40+ countries.

This allowed them to create a holistic view of net prices and volumes across markets, highlighting historical bidding patterns.

Through AI-powered analysis and forecasts, Vamstar unveiled crucial insights into tender dynamics and competitor strategies, providing a clear roadmap for strategic decision-making.

With Vamstar’s comprehensive insights, the two companies were able to re-negotiate their geographical licensing agreement to better align with market realities and increase their investment in the partnership by a remarkable $1.6 billion.

The AI-led insights clarified previously hidden patterns, empowering them to confidently chart a future strategy.

By overcoming the limitations of traditional market research methods and providing comprehensive, data-driven insights, Vamstar enabled the two companies to adapt their investment strategies, leading to a recalibrated partnership and an impressive investment increase.

The result demonstrates the power of AI in the pharmaceutical industry, helping organisations uncover hidden opportunities and navigate competitive landscapes more effectively.